DC
Decheng Capital Portfolio holdings
AUM
$396M
This Quarter Return
+76.72%
1 Year Return
-5.21%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$746M
AUM Growth
+$746M
(+108%)
Cap. Flow
+$221M
Cap. Flow
% of AUM
29.7%
Top 10 Holdings %
Top 10 Hldgs %
93.39%
Holding
31
New
7
Increased
2
Reduced
2
Closed
9
Top Buys
| 1 |
CG Oncology
CGON
|
$240M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$48.9M |
| 3 |
4D Molecular Therapeutics
FDMT
|
$11.1M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$8.37M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$7.39M |
Top Sells
| 1 |
Pacific Biosciences
PACB
|
$28.8M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$19.6M |
| 3 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$14.9M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
argenx
ARGX
|
$10.4M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALPN
1
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $330M | 44.22% | 8,317,924 +1,234,636 | +17% | +$48.9M |
|
|
2
CG Oncology
CGON
$2.04B
| $240M | 32.14% | +5,458,810 | New | +$240M |
|
3
Zentalis Pharmaceuticals
ZNTL
$122M
| $33.1M | 4.44% | 2,099,583 | – | – |
|
4
Illumina
ILMN
$15.8B
| $17.7M | 2.38% | 129,067 +48,208 | +60% | +$6.62M |
|
5
BeyondSpring
BYSI
$69.4M
| $17.7M | 2.37% | 4,958,143 | – | – |
|
6
Arcus Biosciences
RCUS
$1.13B
| $16.4M | 2.2% | 869,790 | – | – |
|
7
Krystal Biotech
KRYS
$4.27B
| $11.7M | 1.57% | 65,772 | – | – |
|
|
8
4D Molecular Therapeutics
FDMT
$288M
| $11.1M | 1.49% | +347,835 | New | +$11.1M |
|
9
Equillium
EQ
$62.2M
| $10.3M | 1.38% | 4,447,308 | – | – |
|
10
Phathom Pharmaceuticals
PHAT
$864M
| $9.03M | 1.21% | 850,000 | – | – |
|
|
11
MoonLake Immunotherapeutics
MLTX
$3.54B
| $8.37M | 1.12% | +166,600 | New | +$8.37M |
|
|
12
Crinetics Pharmaceuticals
CRNX
$2.92B
| $7.39M | 0.99% | +157,958 | New | +$7.39M |
|
13
10x Genomics
TXG
$1.74B
| $7.35M | 0.99% | 195,835 -163,719 | -46% | -$6.14M |
|
14
Cytokinetics
CYTK
$4.23B
| $6.59M | 0.88% | +94,043 | New | +$6.59M |
|
15
Legend Biotech
LEGN
$6.41B
| $4.84M | 0.65% | +86,363 | New | +$4.84M |
|
16
Merus
MRUS
$4.98B
| $4.58M | 0.61% | +101,798 | New | +$4.58M |
|
17
Aura Biosciences
AURA
$389M
| $4.05M | 0.54% | 515,555 | – | – |
|
|
HLTH
18
DELISTED
Cue Health Inc. Common Stock
HLTH
| $1.7M | 0.23% | 8,980,909 | – | – |
|
19
Pyxis Oncology
PYXS
$79.4M
| $1.39M | 0.19% | 326,810 | – | – |
|
|
WHWK
20
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $1.23M | 0.17% | 526,329 | – | – |
|
21
GeneDx Holdings
WGS
$3.72B
| $946K | 0.13% | 103,604 | – | – |
|
22
AtriCure
ATRC
$1.84B
| $815K | 0.11% | 26,797 -19,462 | -42% | -$592K |
|
|
23
argenx
ARGX
$43.6B
| – | – | -27,429 | Closed | -$10.4M |
|
24
Lantheus
LNTH
$3.73B
| – | – | -92,196 | Closed | -$5.72M |
|
|
25
Pacific Biosciences
PACB
$393M
| – | – | -2,940,361 | Closed | -$28.8M |
|